186 related articles for article (PubMed ID: 26901393)
1. Ex Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in Melanomas.
Kryza D; Debordeaux F; Azéma L; Hassan A; Paurelle O; Schulz J; Savona-Baron C; Charignon E; Bonazza P; Taleb J; Fernandez P; Janier M; Toulmé JJ
PLoS One; 2016; 11(2):e0149387. PubMed ID: 26901393
[TBL] [Abstract][Full Text] [Related]
2. (99m)Tc-MAG3-aptamer for imaging human tumors associated with high level of matrix metalloprotease-9.
Da Rocha Gomes S; Miguel J; Azéma L; Eimer S; Ries C; Dausse E; Loiseau H; Allard M; Toulmé JJ
Bioconjug Chem; 2012 Nov; 23(11):2192-200. PubMed ID: 23043415
[TBL] [Abstract][Full Text] [Related]
3. Tumor targeting by an aptamer.
Hicke BJ; Stephens AW; Gould T; Chang YF; Lynott CK; Heil J; Borkowski S; Hilger CS; Cook G; Warren S; Schmidt PG
J Nucl Med; 2006 Apr; 47(4):668-78. PubMed ID: 16595502
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models.
Sprague JE; Li WP; Liang K; Achilefu S; Anderson CJ
Nucl Med Biol; 2006 Feb; 33(2):227-37. PubMed ID: 16546677
[TBL] [Abstract][Full Text] [Related]
5. In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.
Ren G; Webster JM; Liu Z; Zhang R; Miao Z; Liu H; Gambhir SS; Syud FA; Cheng Z
Amino Acids; 2012 Jul; 43(1):405-13. PubMed ID: 21984380
[TBL] [Abstract][Full Text] [Related]
6. Molecular Imaging of P-glycoprotein in Chemoresistant Tumors Using a Dual-Modality PET/Fluorescence Probe.
Wang M; Mao C; Wang H; Ling X; Wu Z; Li Z; Ming X
Mol Pharm; 2017 Oct; 14(10):3391-3398. PubMed ID: 28813596
[TBL] [Abstract][Full Text] [Related]
7. Development of new PTK7-targeting aptamer-fluorescent and -radiolabelled probes for evaluation as molecular imaging agents: Lymphoma and melanoma in vivo proof of concept.
Calzada V; Moreno M; Newton J; González J; Fernández M; Gambini JP; Ibarra M; Chabalgoity A; Deutscher S; Quinn T; Cabral P; Cerecetto H
Bioorg Med Chem; 2017 Feb; 25(3):1163-1171. PubMed ID: 28089349
[TBL] [Abstract][Full Text] [Related]
8. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.
Milenic DE; Wong KJ; Baidoo KE; Nayak TK; Regino CA; Garmestani K; Brechbiel MW
MAbs; 2010; 2(5):550-64. PubMed ID: 20716957
[TBL] [Abstract][Full Text] [Related]
9. Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues.
Chen J; Cheng Z; Hoffman TJ; Jurisson SS; Quinn TP
Cancer Res; 2000 Oct; 60(20):5649-58. PubMed ID: 11059756
[TBL] [Abstract][Full Text] [Related]
10. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase 9 targeting peptides: syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model.
Ujula T; Huttunen M; Luoto P; Peräkylä H; Simpura I; Wilson I; Bergman M; Roivainen A
Bioconjug Chem; 2010 Sep; 21(9):1612-21. PubMed ID: 20795647
[TBL] [Abstract][Full Text] [Related]
12. Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors.
Xiang D; Zheng C; Zhou SF; Qiao S; Tran PH; Pu C; Li Y; Kong L; Kouzani AZ; Lin J; Liu K; Li L; Shigdar S; Duan W
Theranostics; 2015; 5(10):1083-97. PubMed ID: 26199647
[TBL] [Abstract][Full Text] [Related]
13. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
Qi S; Hoppmann S; Xu Y; Cheng Z
Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
[TBL] [Abstract][Full Text] [Related]
14. PET imaging of EGFR expression using an
Cheng S; Jacobson O; Zhu G; Chen Z; Liang SH; Tian R; Yang Z; Niu G; Zhu X; Chen X
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):948-956. PubMed ID: 30069577
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor.
Deng H; Wang H; Wang M; Li Z; Wu Z
Mol Pharm; 2015 Aug; 12(8):3054-61. PubMed ID: 26162008
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
[TBL] [Abstract][Full Text] [Related]
17. Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes.
Zeng Z; Parekh P; Li Z; Shi ZZ; Tung CH; Zu Y
Theranostics; 2014; 4(9):945-52. PubMed ID: 25057318
[TBL] [Abstract][Full Text] [Related]
18. Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells.
Noaparast Z; Hosseinimehr SJ; Piramoon M; Abedi SM
J Drug Target; 2015; 23(6):497-505. PubMed ID: 25673264
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.
Tafreshi NK; Huang X; Moberg VE; Barkey NM; Sondak VK; Tian H; Morse DL; Vagner J
Bioconjug Chem; 2012 Dec; 23(12):2451-9. PubMed ID: 23116461
[TBL] [Abstract][Full Text] [Related]
20. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study.
Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
EJNMMI Res; 2012 Jun; 2(1):25. PubMed ID: 22682002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
